José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
José Octavio Alva Bucio, Chief Operating Officer (COO) at Genbio, shared a post on LinkedIn:
“Latin America appears to be entering a new phase in the conversation surrounding blood donation, plasma, and plasma-derived medicinal products.
In recent weeks, important regulatory developments have taken place across the region, reflecting a significant shift: plasma and plasma-derived therapies are beginning to occupy an increasingly strategic position within healthcare systems.
For example, in Argentina, the exclusively voluntary blood donation model was recently reinforced through the formal elimination of replacement donation within the healthcare system. Meanwhile, in Mexico, regulatory and technical efforts related to the utilization and industrial processing of recovered plasma continue to advance — although still largely unnoticed by many observers.
These are distinct and seemingly unrelated approaches; however, both reflect a shared regional reality: Latin America is beginning to engage more deeply with, and make decisions about, issues that for many years remained largely outside the sphere of public debate and policy action:
- Plasma availability
- Blood donation models
- Health sovereignty
- Industrial processing capacity
- Sustainable access to plasma-derived medicinal products
What is particularly noteworthy is that these developments are taking place within a global context in which demand for immunoglobulins, albumin, and other plasma-derived therapies continues to grow rapidly. This trend will inevitably push healthcare systems to confront a fundamental question — and the sooner this occurs, the better:
How can we build sustainable models capable of guaranteeing long-term access, safety, and sufficiency of blood components and plasma-derived medicines?
Beyond the differences in the maturity of regulatory agencies across the region, the central challenge for each country will be to develop frameworks capable of balancing:
- Ethics
- Sustainability
- Industrial capacity
- Patient access
For this reason, I believe that the progress we are witnessing across the region clearly demonstrates that these issues are finally beginning to be taken seriously.
I am convinced that the evolution of these discussions over the coming months will lead us toward a new level of engagement, collaboration, and network-building.
The conversation continues.”
Stay updated with Hemostasis Today.
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow
-
May 23, 2026, 16:19Sitthiwut Chaturamaytanon: 6 Days Advancing aHUS and PNH Care in Thailand Through Collaboration
-
May 23, 2026, 14:48Sam Zeraatain Nejad Davani: Off-Pump Surgery for COVID-19 Right Atrial Thrombosis
-
May 23, 2026, 14:42How Should Evidence Be Interpreted in Modern Hemophilia Care? – GARDEN
-
May 23, 2026, 12:52Fernanda Orsi: Honor to Be Speaking on ITP Diiferential Diagnosis at the 2026 Highlights of ASH
-
May 23, 2026, 12:46Jayagowri Karthikeyan: Grateful to Receive NBEMS President’s Gold Medal for Excellence In Immunohematology and Blood Transfusion
-
May 23, 2026, 12:40Aryabhatta Sadhu: Redefining Transfusion Medicine Across Obstetrics, Gynecology, and Fetal Medicine
-
May 23, 2026, 12:03Kiana Mohammadian: Do Anti-Inflammatory Cytokines Modulate Thrombosis?